commitment

Tigermed also plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% may be used for dividends or share buybacks.

A commitment by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.

泰格醫藥還計劃將約60%的淨現金收益用於海外臨床CRO擴張和併購,20%用於日常運營,剩餘的約20%可能用於分紅或股票回購。
stockintelligencenewsPublished 2026-11-11 Read source

Discussion

0/2000

Related claims

More claims by 瑞銀

All claims by 瑞銀